July 19, 2011 14:16 ET

eResearch Issues Initiating Report on Chemaphor Inc.

TORONTO, ONTARIO--(Marketwire - July 19, 2011) - Chemaphor Inc. (TSX VENTURE:CFR) is a biotechnology company operating in the animal and human health marketplaces. Its proprietary products are designed to provide improvements in health for pets (dogs, cats & horses) and, eventually, humans.

The Company currently sells its products, i.e., Oximunol™ Chewable Tablets and its in-licensed Vet-Stem™ Regenerative Cell Therapy, to consumers through the veterinary clinic channel.

Chemaphor Inc. is on the brink of profitability. Its transition towards achieving a positive "net earnings" status is being driven by the initiation of revenue from its pet-wellness products and orchestrated by the experienced executive talent recently hired from the animal health market industry. This is supported by the growing number of dogs and cats as companion pets, the concomitant growth in the natural-health market for pets, and the equally increasing importance of veterinarian clinics as a pet-wellness distribution network. Chemaphor is leveraging off all three of these growth drivers.

This Press Release was prepared by eResearch and was not vetted by Chemaphor Inc. Further, the Recommendation and Target Prices contained in this Press Release and in the Initiating Report are strictly those of eResearch and, due to securities laws, are not endorsed by Chemaphor Inc.

eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.

Chemaphor Inc. paid eResearch a fee to conduct research on the Company, on an Annual Continuous Coverage basis.

For FREE access to all eResearch reports and articles, go to

Contact Information